Merck will have exclusive rights to NanoBio's NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive rights for use in an intranasal seasonal flu and/or universal seasonal flu vaccine. NanoBio will receive an upfront payment and is eligible to receive development and regulatory milestones, as well as royalties on sales of any Merck RSV or flu vaccines that use the NE adjuvant technology.
The NanoStat technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types, which, according to the company, is effective when administered via intranasal, intramuscular or subcutaneous vaccination.
"We've collaborated with Merck on research in RSV since 2011 and are very pleased to broaden our relationship with this license agreement covering vaccine candidates for two respiratory diseases," said David Peralta, chief executive officer of NanoBio. "Merck's demonstrated leadership in developing and marketing vaccines makes them an ideal partner for NanoBio."